MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Ulixacaltamide Demonstrates Superiority Over Placebo as Monotherapy and as Add-on to Propranolol in Essential Tremor: Phase 3 ESSENTIAL3 Study 1

    M. Souza, S. Petrou, M. Sniecinski, C. Santos, M. Giroux, M. Steidle, J. Farmer, S. Brillman, A. Shtilbans (Boston, USA)

    Objective: To evaluate efficacy of ulixacaltamide, a selective T-type calcium channel modulator, versus placebo in adults with essential tremor (ET) as monotherapy and as add-on…
  • 2026 International Congress

    Integrating Multidisciplinary, Family-Centered Care to Optimize Functional Outcomes in Children with Cerebral Palsy.

    T. Voloshyn (TRUSKAVETS, Ukraine)

    Objective: Optimal management of Cerebral Palsy requires coordinated, evidence-based interventions that address both motor and non-motor domains across the lifespan.  Background: Randomized controlled trials (RCTs)…
  • 2026 International Congress

    A Randomized Controlled Trial Evaluating Ankle Pump Combined with Compression Abdominal Belts on Orthostatic Hypotension in Patients with Parkinson’s Disease

    Z. Ruan, YY. Zhang, WH. Guo, JY. Liu (Beijing, China)

    Objective: To investigate the short-term efficacy of ankle pump exercise combined with automated compression abdominal belts on orthostatic hypotension (OH) and orthostatic intolerance symptoms in…
  • 2026 International Congress

    Acute administration of methylphenidate modulates functional connectivity during the processing of irrelevant stimuli in Parkinson’s disease patients

    N. Fogelson, L. Li, B. Tan, E. Martinez Lopez, M. Roson Gonzalez, M. Fernandez Delolmo, T. Gurevich, L. Vela Desojo (Fuenlabrada, Spain)

    Objective: Examine the effects of a single dose of methylphenidate (MPD), on event-related functional connectivity (FC), in patients with Parkinson’s disease (PD). Background: Recent studies…
  • 2026 International Congress

    An artificial intelligence-based model to predict Parkinson’s disease risk: the AI-PRA study protocol.

    SV. Virameteekul, S. Hadjidimitriou, I. Gerasimou, C. Sotirakis, L. Hadjileontiadis, M. Almarcha-Menargues, B. Falkenburger, O. Sánchez-Soliño, K. Michailidou, M. Zanti, P. Chairta, K. Christodoulou, M. Kurtis, M. Fabbri, N. Del Campo, A. Noyce, E. de Pablo-Fernández (London, United Kingdom)

    Objective: To present the protocol of the Artificial Intelligence-based Parkinson’s Risk Assessment (AI-PRA) study which aims to validate a novel personalised PD risk prediction model…
  • 2026 International Congress

    The Registry for Sleep and Circadian Health Quality in Parkinson’s Disease (ReSCQu-PD)

    J. Thomas, J. Cohen (Jacksonville, USA)

    Objective: To assess the feasibility of longitudinal data collection using actigraphy and questionnaires in a clinic-based PD population, characterize the variability of sleep and circadian…
  • 2026 International Congress

    Efficacy of Novel Antipsychotic Agents on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis of 2,533 Patients

    I. Serag (Mansoura, Egypt)

    Objective: To systematically evaluate and quantitatively synthesize evidence on the effects of novel antipsychotic agents (Clozapine, Olanzapine, Risperidone, and Aripiprazole) on cognitive domains in Parkinson’s…
  • 2026 International Congress

    Intrafamilial Phenotypic Diversity Associated with Coexisting LRRK2 G2385R and a Novel GCH1 Variant: A Case Report

    CE. Wang, YF. Sung (Taipei, Taiwan)

    Objective: To describe intrafamilial phenotypic variability associated with the coexisting LRRK2 G2385R and a novel GCH1 variant in a family presenting with parkinsonism and dystonia…
  • 2026 International Congress

    Suicidal Ideation and the Hippocampal Histaminergic System in Huntington’s Disease: A PET Study

    P. Eze, C. Madrigal-Esquivel, O. Makos, A. Rangel-Cristales, J. Valera-Bermejo, M. Moretto, N. Martin, P. Tall, J. Staunton, M. Hartmann, F. Turkheimer, J. Badenoch, M. Veronese, N. Palasits, A. Wood, S. Williams, D. van Wamelen (London, United Kingdom)

    Objective: To determine whether presence and severity of suicidal ideation (SI) are associated with hippocampal volume and histamine H3 receptor (H3R) PET uptake in people with Huntington’s disease (PwHD). Background: Suicidal ideation occurs in approximately 8–27% of PwHD, yet its causes remain unclear​(1–3)​. The…
  • 2026 International Congress

    Digital Innovation in Parkinson’s Disease – Governing Care and Managing Autonomy

    B. Schmitz-Luhn (Bonn, Germany)

    Objective: The study analyzes the regulatory implications of digital technologies in Parkinson’s disease, with particular focus on (1) improvement of care and reduction of intensive…
  • « Previous Page
  • 1
  • …
  • 93
  • 94
  • 95
  • 96
  • 97
  • …
  • 208
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley